Ixekizumab for treatment of refractory acute generalized exanthematous pustulosis caused by hydroxychloroquine.

Munshi, Mohammad; Junge, Alexandra; Gadaldi, Karolina; Yawalkar, Nikhil; Heidemeyer, Kristine (2020). Ixekizumab for treatment of refractory acute generalized exanthematous pustulosis caused by hydroxychloroquine. JAAD case reports, 6(7), pp. 634-636. Elsevier 10.1016/j.jdcr.2020.05.014

[img]
Preview
Text
ixekizumab.pdf - Published Version
Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND).

Download (1MB) | Preview

Item Type:

Journal Article (Further Contribution)

Division/Institute:

04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Dermatology

UniBE Contributor:

Gadaldi, Karolina; Yawalkar, Nikhil and Heidemeyer, Kristine

Subjects:

600 Technology > 610 Medicine & health

ISSN:

2352-5126

Publisher:

Elsevier

Language:

English

Submitter:

Sandra Nyffenegger

Date Deposited:

14 Dec 2020 15:42

Last Modified:

13 Mar 2021 11:08

Publisher DOI:

10.1016/j.jdcr.2020.05.014

PubMed ID:

32613058

Uncontrolled Keywords:

AGEP, acute generalized exanthematous pustulosis IL, interleukin acute generalized exanthematous pustulosis hydroxychloroquine ixekizumab

BORIS DOI:

10.7892/boris.148344

URI:

https://boris.unibe.ch/id/eprint/148344

Actions (login required)

Edit item Edit item
Provide Feedback